Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-28T02:20:56.274Z Has data issue: false hasContentIssue false

Amyotrophic Lateral Sclerosis: Interleukin-6 Levels in Cerebrospinal Fluid

Published online by Cambridge University Press:  18 September 2015

Charles Krieger*
Affiliation:
Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada V6T 2B5
Thomas L. Perry
Affiliation:
Department of Pharmacology and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada V6T 2B5
Hermann J. Ziltener
Affiliation:
The Biomedical Research Centre, The University of British Columbia, Vancouver, British Columbia, Canada V6T 2B5
*
Division of Neurology, Department of Medicine, University Hospital, U.B.C. site, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Recent observations indicate that antibodies to gangliosides are found in many patients with amyotrophic lateral sclerosis (ALS). If antigen-antibody complexes occur in ALS, elevations of cytokine levels might be expected, among them the cytokine interleukin-6 (IL-6). IL-6 is secreted by activated monocytes and other cell types and is an important mediator of the inflammatory response. We have measured cerebrospinal fluid (CSF) IL-6 levels in patients with ALS and compared them with those in psychiatric and neurodegenerative disorders not believed to be due to immune disorders of the central nervous system. We found no significant differences in CSF IL-6 levels between these groups.

Type
Articles
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Drachman, DB, Kuncl, RW., Amyotrophic lateral sclerosis: an unconventional autoimmune disease? Ann Neurol 1989; 26: 269274.CrossRefGoogle ScholarPubMed
2.Pestronk, A, Adams, RN, Clawson, L, et al. Serum antibodies to GM, ganglioside in amyotrophic lateral sclerosis. Neurology 1988; 38: 14571461.CrossRefGoogle Scholar
3.Shy, ME, Evans, VA, Lublin, FD, et al. Antibodies to GMl and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol 1989; 25: 511513.CrossRefGoogle Scholar
4.Pestronk, A, Adams, RN, Cornblath, D, et al. Patterns of serum IgM antibodies to GM, and GDla gangliosides in amyotrophic lateral sclerosis. Ann Neurol 1989; 25: 98102.CrossRefGoogle Scholar
5.Latov, N, Hays, AP, Donofrio, PD, et al. Monoclonal IgM with unique specificity to gangliosides GM, and GDlb and to lacto-N-tetraose associated with human motor neuron disease. Neurology 1988; 38: 763768.CrossRefGoogle Scholar
6.Ling, Z-D, Ziltener, HJ, Webb, BT, et al. Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cell Immunol (in press).Google Scholar
7.Wong, GG, Clark, SC.Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9: 137139.CrossRefGoogle ScholarPubMed
8.Kamegai, M, Niijima, K, Kunishita, T, et al. Interleukin 3 as a trophic factor for central cholinergic neurons in vitro and in vivo. Neuron 1990; 2: 429436.CrossRefGoogle Scholar
9.Arakawa, Y, Sendtner, M, Thoenen, H.Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other embryonic factors and cytokines. J Neurosci 1990; 10: 35073515.CrossRefGoogle ScholarPubMed
10.Houssiau, FA, Bukasa, K, Sindic, CJM, et al. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cere-brospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 1988; 71: 320323.Google Scholar
11.Gueme, P-A, Zuraw, BL, Vaughan, JH, et al. Synovium as a source of interleukin 6 in vitro. J Clin Invest 1989; 83: 585592.Google Scholar
12.Aarden, LA, De Groot, ER, Schaap, OL, et al. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17: 14111416.CrossRefGoogle ScholarPubMed
13.Clark-Lewis, IR, Aebersold, R, Ziltener, HJ, et al. Automated chemical synthesis of a protein growth factor for hemopoetic cells, Interleukin-3. Science 1986; 231: 134139.CrossRefGoogle Scholar
14.Leppert, D, Frei, K, Gallo, P, et al. Brain tumors: detection of B-cell stimulatory factor-2/ interleukin-6 in the absence of oligoclonal bands of immunoglobulins. J Neuroimmunol 1989; 24: 259264.CrossRefGoogle ScholarPubMed
15.Frei, K, Malipiero, UV, Leist, TP, et al. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 1989; 19: 689694.CrossRefGoogle ScholarPubMed